Cantargia AB (publ) (CANTA.ST)
SEK 1.83
(1.05%)
SEK 1.83
(1.05%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -3.45 Million SEK | 6.53% |
| 2022 | -3.69 Million SEK | -7.14% |
| 2021 | -3.44 Million SEK | -6.1% |
| 2020 | -3.24 Million SEK | -26966.67% |
| 2019 | -12 Thousand SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 100.0% |
| 2016 | -35.49 Million SEK | -403.8% |
| 2015 | -7.04 Million SEK | -101.57% |
| 2014 | -3.49 Million SEK | 39.46% |
| 2013 | -5.77 Million SEK | -315315.6% |
| 2012 | -1830.30 SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -862 Thousand SEK | -0.12% |
| 2024 Q1 | -861 Thousand SEK | 0.23% |
| 2023 Q3 | -863 Thousand SEK | 0.0% |
| 2023 Q1 | -863 Thousand SEK | 19.35% |
| 2023 Q4 | -863 Thousand SEK | 0.0% |
| 2023 Q2 | -863 Thousand SEK | 0.0% |
| 2023 FY | -3.45 Million SEK | 6.53% |
| 2022 Q3 | -874 Thousand SEK | 0.0% |
| 2022 FY | -3.69 Million SEK | -7.14% |
| 2022 Q1 | -874 Thousand SEK | -0.58% |
| 2022 Q4 | -1.07 Million SEK | -22.43% |
| 2022 Q2 | -874 Thousand SEK | 0.0% |
| 2021 Q2 | -858 Thousand SEK | 0.0% |
| 2021 Q1 | -858 Thousand SEK | 0.0% |
| 2021 Q3 | -861 Thousand SEK | -0.35% |
| 2021 Q4 | -869 Thousand SEK | -0.93% |
| 2021 FY | -3.44 Million SEK | -6.1% |
| 2020 FY | -3.24 Million SEK | -26966.67% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | -12 Thousand SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2017 FY | - SEK | 100.0% |
| 2017 Q3 | -7.62 Million SEK | 32.92% |
| 2017 Q2 | -11.37 Million SEK | 27.38% |
| 2017 Q1 | -15.66 Million SEK | 0.95% |
| 2017 Q4 | 34.66 Million SEK | 554.35% |
| 2016 Q2 | -5.19 Million SEK | -2.71% |
| 2016 Q3 | -9.43 Million SEK | -81.67% |
| 2016 Q4 | -15.81 Million SEK | -67.59% |
| 2016 FY | -35.49 Million SEK | -403.8% |
| 2016 Q1 | -5.05 Million SEK | -169.51% |
| 2015 Q4 | -1.87 Million SEK | -82.14% |
| 2015 FY | -7.04 Million SEK | -101.57% |
| 2015 Q3 | -1.03 Million SEK | 64.48% |
| 2015 Q2 | -2.9 Million SEK | -134.06% |
| 2015 Q1 | -1.23 Million SEK | -60.49% |
| 2014 FY | -3.49 Million SEK | 39.46% |
| 2014 Q1 | -936.32 Thousand SEK | 49.56% |
| 2014 Q3 | -902.66 Thousand SEK | -2.11% |
| 2014 Q4 | -772 Thousand SEK | 14.47% |
| 2014 Q2 | -884 Thousand SEK | 5.59% |
| 2013 FY | -5.77 Million SEK | -315315.6% |
| 2013 Q4 | -1.85 Million SEK | 0.0% |
| 2012 FY | -1830.30 SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 97.852% |
| Ziccum AB (publ) | -23.28 Million SEK | 85.18% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.996% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 108.259% |
| Mendus AB (publ) | 28.48 Million SEK | 112.114% |
| Genovis AB (publ.) | 54 Million SEK | 106.391% |
| Intervacc AB (publ) | -13.79 Million SEK | 74.982% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 258.959% |
| Active Biotech AB (publ) | -1.67 Million SEK | -106.03% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 134.638% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 112.867% |
| Aptahem AB (publ) | 2.63 Million SEK | 231.184% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -0.877% |
| Kancera AB (publ) | -1.96 Million SEK | -75.623% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 4581.818% |
| Fluicell AB (publ) | 1.73 Million SEK | 298.562% |
| Saniona AB (publ) | 11.78 Million SEK | 129.293% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 32.558% |
| Biovica International AB (publ) | 6.87 Million SEK | 150.182% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 85.178% |
| AcouSort AB (publ) | 8.38 Million SEK | 141.137% |
| Xintela AB (publ) | 78 Thousand SEK | 4524.359% |
| Abliva AB (publ) | -35.66 Million SEK | 90.323% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 97.651% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 222.943% |
| OncoZenge AB (publ) | 3000.00 SEK | 115133.333% |
| Amniotics AB (publ) | -1.93 Million SEK | -78.808% |
| 2cureX AB (publ) | -37.48 Million SEK | 90.794% |
| CombiGene AB (publ) | -21.29 Million SEK | 83.791% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -715.839% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.305% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.218% |
| Corline Biomedical AB | 28.38 Million SEK | 112.16% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 97.188% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 89.972% |
| I-Tech AB | 27.56 Million SEK | 112.519% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 104.864% |
| Cyxone AB (publ) | 2.61 Million SEK | 232.172% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 201.411% |
| Biosergen AB | -456 Thousand SEK | -656.798% |
| NextCell Pharma AB | -43.74 Million SEK | 92.112% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 62.465% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 130.762% |
| Nanologica AB (publ) | -76 Thousand SEK | -4440.789% |
| SynAct Pharma AB | -778 Thousand SEK | -343.573% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -1688.083% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 73.294% |
| Lipum AB (publ) | 53 Thousand SEK | 6611.321% |
| BioInvent International AB (publ) | 71.46 Million SEK | 104.829% |
| Alzinova AB (publ) | 19.87 Million SEK | 117.364% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 109.507% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 335.882% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -22906.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 308.142% |
| Simris Alg AB (publ) | 2 Million SEK | 271.948% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 3.603% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 109.752% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -228.98% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 210.15% |